Thromboxane Production in Morbidly Obese Subjects
Thromboxane Production in Morbidly Obese Subjects
复制标题
DOI：
10.1016/j.amjcard.2011.01.053
复制
发表时间：
2011-06-01
影响因子：
2.8
通讯作者：
Crea, Filippo
中科院分区：
文献类型：
--
作者：
Graziani, Francesca;Biasucci, Luigi M.;Crea, Filippo
尸检研究表明，令人惊讶的是，病态肥胖者的冠状动脉粥样硬化程度低于肥胖者。然而，这种对动脉粥样硬化的明显保护作用的原因尚不清楚。血栓素A2是血小板活化的标志，肥胖者的血栓素A2水平高于消瘦的受试者，这可能是他们心血管风险增加的线索。然而，关于病态肥胖者血栓素A2的数据缺乏；因此，我们假设病态肥胖者较低的血栓素A2水平可能在他们较低的动脉粥样硬化血栓负荷中起作用。我们测定了17例瘦肉者(体重指数22.9+/-1.6 kg/m(2))、25例肥胖者(BMI 32.6+/-2.4 kg/m(2))和23例病态肥胖者(BMI 48.6+/-7.1 kg/m(2))的血清血栓素B2(TxB2)、超敏C反应蛋白(hs-CRP)和瘦素水平。瘦肉组血清TXB2水平低于肥胖组(P=0.046)，病态肥胖组低于瘦肉组和肥胖组(P=0.015和P<0.05)。
Postmortem studies have demonstrated that morbidly obese subjects, surprisingly, have less coronary atherosclerosis than obese subjects. However, the reasons for this apparent protection from atherosclerosis are not yet clear. Thromboxane A2, a marker of platelet activation, is greater in obese subjects than in lean subjects, and this might be a clue to their increased cardiovascular risk. However, data on thromboxane A2 in morbidly obese subjects are lacking; therefore, we hypothesized that lower levels of thromboxane A2 in morbidly obese subjects might play a role in their lower atherothrombotic burden. We measured the serum levels of thromboxane B2 (TxB2), a stable metabolite of thromboxane A2, high-sensitivity C-reactive protein (hs-CRP) and leptin in 17 lean subjects (body mass index [BMI] 22.9 +/- 1.6 kg/m(2)), 25 obese subjects (BMI 32.6 +/- 2.4 kg/m(2)), and 23 morbidly obese subjects (BMI 48.6 +/- 7.1 kg/m(2)), without insulin resistance, diabetes, or overt cardiovascular disease. The serum TxB2 levels were lower in the lean subjects than in the obese subjects (p = 0.046) and in the morbidly obese subjects than in the lean and obese subjects (p = 0.015 and p